donanemab

Home
Ligands
donanemab

GtoPdb Ligand ID: 8357

Comment: Donanemab (LY3002813) is a monoclonal antibody developed from the murine monoclonal mE8-IgG2a [1]. It binds to N-terminally, pyroglutamate-modified amyloid β proteins (abbreviated as Aβ_p3-x or N3pG) which are found extensively in the amyloid plaques of the brains of Alzheimer's disease (AD) patients. The removal of Aβ_p3-x is being investigated as a novel mechanism to treat AD.

References
1. Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F et al.. (2012) A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. Neuron, 76 (5): 908-20. [PMID:23217740]
2. Lowe SL, Willis BA, Hawdon A, Natanegara F, Chua L, Foster J, Shcherbinin S, Ardayfio P, Sims JR. (2021) Donanemab (LY3002813) dose-escalation study in Alzheimer's disease. Alzheimers Dement (N Y), 7 (1): e12112. [PMID:33614890]
3. Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, Gueorguieva I, Hauck PM, Brooks DA, Mintun MA et al.. (2022) Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA Neurol, 79 (10): 1015-1024. [PMID:36094645]
4. Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul ES et al.. (2023) Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA, Epub ahead of print. DOI: 10.1001/jama.2023.13239
5. Wessels AM, Dennehy EB, Dowsett SA, Dickson SP, Hendrix SB. (2023) Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings. Neurol Clin Pract, 13 (2): e200127. [PMID:36891463]

References

1. Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F et al.. (2012)
A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice.
Neuron, 76 (5): 908-20. [PMID:23217740]

2. Lowe SL, Willis BA, Hawdon A, Natanegara F, Chua L, Foster J, Shcherbinin S, Ardayfio P, Sims JR. (2021)
Donanemab (LY3002813) dose-escalation study in Alzheimer's disease.
Alzheimers Dement (N Y), 7 (1): e12112. [PMID:33614890]

3. Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, Gueorguieva I, Hauck PM, Brooks DA, Mintun MA et al.. (2022)
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
JAMA Neurol, 79 (10): 1015-1024. [PMID:36094645]

4. Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul ES et al.. (2023)
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
JAMA, Epub ahead of print. DOI: 10.1001/jama.2023.13239

5. Wessels AM, Dennehy EB, Dowsett SA, Dickson SP, Hendrix SB. (2023)
Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings.
Neurol Clin Pract, 13 (2): e200127. [PMID:36891463]